Attributes | Values |
---|
rdf:type
| |
Description
| - We evaluated the anti-tumour effects of the DNA methyltransferase inhibitor 5-azacytidine (5AC) The 5AC therapy was combined with immunotherapy, using a murine model for HPV16-associated tumours. We have demonstrated 5AC additive effects against MHC class I-positive and -deficient tumours when combined with unmethylated CpG oligodeoxynucleotides (CpG ODN) or with IL-12-producing cellular vaccine. The efficacy of the combined chemoimmunotherapy against originally MHC class I-deficient tumours was partially dependent on the CD8+-mediated immune responses. Increased cell surface expression of MHC class I cell molecules, associated with upregulation of the antigen-presenting machinery-related genes, as well as of genes encoding selected components of the IFNγ signalling pathway in tumours explanted from 5AC-treated animals, were observed.
- We evaluated the anti-tumour effects of the DNA methyltransferase inhibitor 5-azacytidine (5AC) The 5AC therapy was combined with immunotherapy, using a murine model for HPV16-associated tumours. We have demonstrated 5AC additive effects against MHC class I-positive and -deficient tumours when combined with unmethylated CpG oligodeoxynucleotides (CpG ODN) or with IL-12-producing cellular vaccine. The efficacy of the combined chemoimmunotherapy against originally MHC class I-deficient tumours was partially dependent on the CD8+-mediated immune responses. Increased cell surface expression of MHC class I cell molecules, associated with upregulation of the antigen-presenting machinery-related genes, as well as of genes encoding selected components of the IFNγ signalling pathway in tumours explanted from 5AC-treated animals, were observed. (en)
|
Title
| - Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
- Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status (en)
|
skos:prefLabel
| - Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
- Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status (en)
|
skos:notation
| - RIV/68378050:_____/11:00371265!RIV12-AV0-68378050
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - P(GA301/07/1410), P(GA301/09/1024), P(GAP301/10/2174), Z(AV0Z50520514)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/11:00371265
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - 5-azacytidine; MHC class I downregulation; tumour chemoimmunotherapy (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - British Journal of Cancer
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Reiniš, Milan
- Bieblová, Jana
- Bubeník, Jan
- Indrová, Marie
- Mikyšková, Romana
- Šímová, Jana
- Polláková, Veronika
- Štěpánek, Ivan
|
http://linked.open...ain/vavai/riv/wos
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |
is http://linked.open...avai/riv/vysledek
of | |